Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is ...

Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with ...

Google DeepMind's drug discovery company, Isomorphic Labs, is set to launch human trials of its AI-designed drugs. The company is aiming to use cutting-edge AI to design medicines faster, cheaper ...

Isomorphic was founded in 2021, but it wasn’t until yesterday that the company announced its first external funding—a $600 million round, led by Thrive Capital with participation from GV.

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes ...

Until now, cells dividing by mitosis were thought to grow round and then split into two identical, spherical daughter cells. New research has found that some cells are isomorphic, meaning they ...

Isomorphic Labs sets up U.S. presence, with an eye on clinical trials The Alphabet company, spun off from DeepMind, is hiring a new chief medical officer and adding an office in Cambridge ...

Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. LONDON ...